Related Experiment Video
Updated: Jan 15, 2026

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
Radiobiology and Radioresistance in High-Dose Radiosurgery for Brain Tumors: A Hypothesis-Generating Study Using an
Anastasia Janas1, Carolin Senger2, Kiril Krantchev1
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Neurosurgery, Charitéplatz 1, 10117 Berlin, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Radiation Oncology and Radiotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.
Purpose:
Stereotactic radiosurgery (SRS) is a precise, noninvasive treatment for brain tumors, yet underlying radiobiological mechanisms remain unclear. This study explored long-term dose-dependent tumor response to high-dose SRS in a murine glioma model, focusing on tumor-associated macrophages (TAMs) as key regulators of tumor microenvironment and immune modulation.
Methods And Materials:
Using the intracranial GL261-glioma mouse model, single-dose SRS was administered at either 20 Gy (clinically prescribed dose) or 40 Gy as a dose escalation approach (n = 24/dose). Tumor response was assessed longitudinally using 7T magnetic resonance imaging at predefined intervals (d7, d30, d90, and d180) post-SRS or earlier upon symptom onset. Histological analyses performed at each timepoint evaluated cell proliferation, apoptosis, vascular morphology, blood-brain/tumor-barrier integrity, hypoxia, TAM recruitment, and polarization. Immune cell populations within tumor microenvironment were characterized using flow cytometry. Statistical analyses included a t-test and one-way analysis of variance with Bonferroni or Dunnett correction.
Results:
SRS efficacy was dose-dependent: 40 Gy suppressed tumor growth, whereas 20 Gy led to regrowth in 29% of cases between d30-51 post-SRS, necessitating stratification into responders and nonresponders. Responders demonstrated reduced cell proliferation, sustained apoptosis, and vascular remodeling indicative of vessel normalization. Nonresponders exhibited ≤94.5% increased hypoxia and ≤300-fold increased CXCR4 expression compared with responders. TAM recruitment inversely correlated with tumor volume (r = -0.8619; P = .0056). The M1/M2 ratio in nonresponders was similar to that of matched controls, but 3.8-fold and 4.8-fold lower than in responders at d30 and d90 post-SRS, respectively. Fluorescence-activated cell sorting analysis confirmed an increased M1/M2 ratio by d30 in responders.
Conclusions:
This study offers key insights into longitudinal SRS radiobiology, highlighting the dynamic role of TAMs in sustaining long-term tumor control. Our findings support an association between hypoxia, CXCL12/CXCR4 signaling, and treatment resistance, and suggest a potential SRS-induced vascular normalization that may support improved therapeutic outcomes. Although not designed to establish causality, the data provide a spatially and temporally resolved framework to guide future mechanistic studies and inform more effective SRS-based combination strategies.
More Related Videos
10:52Stereotactic Intracranial Implantation and In vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme
Published on: September 25, 2012
10:48PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017